RecruitingPhase 1NCT06014905

Feasibility of Acquiring Hyperpolarized Imaging in Patients With Meningioma

Pilot/Phase I Study of Feasibility of Acquiring Hyperpolarized Imaging in Patients With Meningioma

Sponsor

Charlie Wang, MD, PhD

Enrollment

50 participants

Start Date

Sep 1, 2023

Study Type

INTERVENTIONAL

Conditions

Meningioma

Summary

This is a Pilot/Phase I clinical study of hyperpolarized 13C (HP 13C) pyruvate injection that includes the acquisition of magnetic resonance (MR) data performed on participants with meningioma to evaluate metabolism and aid in the non-invasive characterization of aggressive tumor behavior

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Hyperpolarized carbon C 13 pyruvate, a procedure called Magnetic Resonance Image (MRI), and others for people with meningioma. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.